FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3015013040> ?p ?o ?g. }

• W3015013040 endingPage "e19420" @default.
• W3015013040 startingPage "e19420" @default.
• W3015013040 abstract "The aim of this study is to evaluate the predictive value of carbohydrate antigen125 (CA125) and carcino embryonic antigen (CEA) expression and its guiding role of choosing chemotherapy regimen in post-operation patients with colorectal carcinoma.The clinical data of all patients, including laboratory data and pathological data, were collected from the electronic medical records. Kaplan-Meier Log rank test, COX regression model and subgroup analyses were employed to assess the correlation between the expression of CA125 and CEA in patients with colorectal carcinoma and the survival, and the effect on chemotherapy efficacy.Kaplan-Meier showed that CA125 expression is negatively related to the progression-free survival (PFS) of the post-operative patients, Median PFS was 1140 days in the patients with high expression, and Median PFS was 1387 days in the patients with low expression (χ = 4.715, P = .030); CEA expression is also negatively associated with the PFS of the post-operative patients, Median PFS was 1197 days in the patients with high expression, and Median PFS was 1424 days in the patients with low expression (χ = 4.992, P = .025). Subgroup analysis also showed that the patients with normal CA125 and CEA had better prognosis, median PFS was 1505 days, and the patients with CA125 and (or) CEA high expression had poor prognosis and median PFS was 1162 days (χ = 13.346, P = .001), and found that there was no statistical difference in patients with oxaliplatin plus capecitabine (XELOX) and oxaliplatin, 5-fluorouracil and Calcium folinate (FOLFOX) chemotherapy in patients with CA125 and CEA low expression. However, in these patients with CA125 or (and) CEA high expression, the median PFS of patients treated with XELOX was 1082 days, and the median PFS of patients treated with FOLFOX chemotherapy was 1335 (χ = 4.547, P = .033).Expression of CA125 and CEA associated with the survival of patients, and have some guiding significance for chemotherapy in patients with colorectal cancer after operation; Compared with XELOX, FOLFOX chemotherapy is more effective for CA125 or (and) CEA high expression patients with colorectal carcinoma." @default.
• W3015013040 created "2020-04-10" @default.
• W3015013040 creator A5014273510 @default.
• W3015013040 creator A5015273050 @default.
• W3015013040 creator A5031351676 @default.
• W3015013040 creator A5032469036 @default.
• W3015013040 creator A5039545143 @default.
• W3015013040 creator A5048226673 @default.
• W3015013040 creator A5077262850 @default.
• W3015013040 date "2020-04-01" @default.
• W3015013040 modified "2023-09-26" @default.
• W3015013040 title "Prognostic value of carbohydrate antigen125 and carcino embryonic antigen expression in patients with colorectal carcinoma and its guiding significance for chemotherapy" @default.
• W3015013040 cites W1918640585 @default.
• W3015013040 cites W2034730912 @default.
• W3015013040 cites W2056028738 @default.
• W3015013040 cites W2062024741 @default.
• W3015013040 cites W2066245403 @default.
• W3015013040 cites W2105239364 @default.
• W3015013040 cites W2110853199 @default.
• W3015013040 cites W2115325071 @default.
• W3015013040 cites W2128988391 @default.
• W3015013040 cites W2140356034 @default.
• W3015013040 cites W2189125461 @default.
• W3015013040 cites W2271974346 @default.
• W3015013040 cites W2414952967 @default.
• W3015013040 cites W2472968487 @default.
• W3015013040 cites W2481607340 @default.
• W3015013040 cites W2777447025 @default.
• W3015013040 cites W2807578475 @default.
• W3015013040 cites W2914275547 @default.
• W3015013040 cites W4291982393 @default.
• W3015013040 doi "https://doi.org/10.1097/md.0000000000019420" @default.
• W3015013040 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7220750" @default.
• W3015013040 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32243362" @default.
• W3015013040 hasPublicationYear "2020" @default.
• W3015013040 type Work @default.
• W3015013040 sameAs 3015013040 @default.
• W3015013040 citedByCount "4" @default.
• W3015013040 countsByYear W30150130402020 @default.
• W3015013040 countsByYear W30150130402022 @default.
• W3015013040 countsByYear W30150130402023 @default.
• W3015013040 crossrefType "journal-article" @default.
• W3015013040 hasAuthorship W3015013040A5014273510 @default.
• W3015013040 hasAuthorship W3015013040A5015273050 @default.
• W3015013040 hasAuthorship W3015013040A5031351676 @default.
• W3015013040 hasAuthorship W3015013040A5032469036 @default.
• W3015013040 hasAuthorship W3015013040A5039545143 @default.
• W3015013040 hasAuthorship W3015013040A5048226673 @default.
• W3015013040 hasAuthorship W3015013040A5077262850 @default.
• W3015013040 hasBestOaLocation W30150130401 @default.
• W3015013040 hasConcept C121608353 @default.
• W3015013040 hasConcept C126322002 @default.
• W3015013040 hasConcept C143998085 @default.
• W3015013040 hasConcept C2776694085 @default.
• W3015013040 hasConcept C2777387746 @default.
• W3015013040 hasConcept C2777909004 @default.
• W3015013040 hasConcept C2778260052 @default.
• W3015013040 hasConcept C2778336483 @default.
• W3015013040 hasConcept C2780456651 @default.
• W3015013040 hasConcept C2780739268 @default.
• W3015013040 hasConcept C2780962732 @default.
• W3015013040 hasConcept C2781413609 @default.
• W3015013040 hasConcept C50382708 @default.
• W3015013040 hasConcept C526805850 @default.
• W3015013040 hasConcept C71924100 @default.
• W3015013040 hasConcept C90924648 @default.
• W3015013040 hasConceptScore W3015013040C121608353 @default.
• W3015013040 hasConceptScore W3015013040C126322002 @default.
• W3015013040 hasConceptScore W3015013040C143998085 @default.
• W3015013040 hasConceptScore W3015013040C2776694085 @default.
• W3015013040 hasConceptScore W3015013040C2777387746 @default.
• W3015013040 hasConceptScore W3015013040C2777909004 @default.
• W3015013040 hasConceptScore W3015013040C2778260052 @default.
• W3015013040 hasConceptScore W3015013040C2778336483 @default.
• W3015013040 hasConceptScore W3015013040C2780456651 @default.
• W3015013040 hasConceptScore W3015013040C2780739268 @default.
• W3015013040 hasConceptScore W3015013040C2780962732 @default.
• W3015013040 hasConceptScore W3015013040C2781413609 @default.
• W3015013040 hasConceptScore W3015013040C50382708 @default.
• W3015013040 hasConceptScore W3015013040C526805850 @default.
• W3015013040 hasConceptScore W3015013040C71924100 @default.
• W3015013040 hasConceptScore W3015013040C90924648 @default.
• W3015013040 hasIssue "14" @default.
• W3015013040 hasLocation W30150130401 @default.
• W3015013040 hasLocation W30150130402 @default.
• W3015013040 hasLocation W30150130403 @default.
• W3015013040 hasLocation W30150130404 @default.
• W3015013040 hasLocation W30150130405 @default.
• W3015013040 hasOpenAccess W3015013040 @default.
• W3015013040 hasPrimaryLocation W30150130401 @default.
• W3015013040 hasRelatedWork W2077919698 @default.
• W3015013040 hasRelatedWork W2123069582 @default.
• W3015013040 hasRelatedWork W2158284184 @default.
• W3015013040 hasRelatedWork W2285747469 @default.
• W3015013040 hasRelatedWork W2366470568 @default.
• W3015013040 hasRelatedWork W2380684846 @default.
• W3015013040 hasRelatedWork W2417717847 @default.
• W3015013040 hasRelatedWork W2529248731 @default.

• next